ESC Premium Access

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - PRO

Congress Presentation

About the speaker

Doctor Milton Packer

Baylor University Medical Center, Dallas (United States of America)
34 presentations
4 followers

7 more presentations in this session

Positioning of the topic - First-line therapies in heart failure with reduced ejection fraction (HFrEF)

Speaker: Professor G. Filippatos (Athens, GR)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - CON

Speaker: Professor A. Voors (Groningen, NL)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal PRO

Speaker: Doctor M. Packer (Dallas, US)

Thumbnail

Sacubitril - Valsartan should be the starting treatment in HFrEF patients - Rebuttal CON

Speaker: Professor A. Voors (Groningen, NL)

Thumbnail

Access the full session

First-line therapies in heart failure with reduced ejection fraction (HFrEF) - ACE inhibitors or sacubitril/valsartan?

Speakers: Doctor M. Packer, Professor G. Filippatos, Professor A. Voors, Doctor M. Packer, Professor A. Voors
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Related content

Open Access

GUIDE-HF - Panel discussion.

27 August 2021

ESC Premium Access

A closer look at heart failure drugs: particular benefits and problems.

27 August 2021

ESC Premium Access

The practicalities of drug treatment in heart failure - Chat Moderator.

27 August 2021

ESC 365 is supported by

logo Novo Nordisk